Infigratinib demonstrated a consistent efficacy of 37.9% ORR; however, owing to insufficient statistical power, definitive conclusions could not be drawn, highlighting the limitations of conducting clinical trials on the ultra-rare disease of FGFR2 mutation-positive cholangiocarcinoma. Here, FGFR2 is linked to cholangiocarcinoma.